张璐 / Zhang Lu
E227｜美国医疗市场AI争夺战：巨头押注，创业公司能赢吗？ adds Zhang Lu as the healthcare-AI investment-side guest and identifies her as founder and managing partner of Fusion Fund. She reads the U.S. medical AI market through Healthcare AI Infrastructure, Medical Billing and Coding Automation, HIPAA-Constrained Medical AI, Vertical Medical Small Models, and startup opportunities that survive because hospitals, pharma companies, and healthcare firms control core data and workflows.
张璐 appears in E230｜1万亿收入预期背后：英伟达的巅峰与软肋 as an investment-side guest interpreting Nvidia’s GTC claims. Her central contribution is to frame the AI infrastructure demand story through Inference as Cash Flow: training is closer to a large one-time build cost, while inference, agents, and long context create continuing token consumption.
She also treats Nvidia’s software moves, including NeMo Cloud and Agent as a Service, as efforts to shape deployment standards and expand token usage rather than merely sell application-layer services. Her caution is that inferencing chips and startup opportunities still exist, but the space narrows when Nvidia’s full-stack ecosystem, model change, and system integration absorb more of the value.
Connections
- Fusion Fund, OpenEvidence, ChatGPT for Healthcare, and Claude for Healthcare - healthcare AI market and product comparison branch added by E227.
- Healthcare AI Infrastructure, Medical Billing and Coding Automation, HIPAA-Constrained Medical AI, and Vertical Medical Small Models - healthcare AI investment frame added by E227.
- Nvidia, Jensen Huang, and AI Infrastructure Full-Stack Moat - platform and moat frame she helps explain.
- AI Inference Cost Structure, Inference as Cash Flow, and Token per Watt - token-demand and efficiency concepts.
- Agent as a Service, NeMo Cloud, and AI Native SaaS Threat - software and agent deployment branch.
- Low-Latency Inference Chip, AI Chip Specialization, and Physical AI - areas where she discusses remaining challengers and future vertical attacks.